



Food and Drug Administration
Rockville, MD 20857

May 18, 2004

Keith Altman
Director of Adverse Event Analyses
Finkelstein and Partners
436 Robinson Avenue
Newburgh, NY 12550

Dear Mr. Altman:

Your petition requesting the Food and Drug Administration to request the amplification of the current Neurontin labeling to properly reflect the significant number of postmarketing reports of completed suicides, suicidal attempts and suicidal ideations was received by this office on 05/18/2004. It was assigned docket number 2004P-0235/CP1 and it was filed on 05/18/2004. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note that the acceptance of the petition for filing is a procedural matter in that it in no way reflects an agency decision on the substantive merits of the petition.

Sincerely,

Lyle D. Jaffe
Division of Dockets Management
Office of Management Programs
Office of Management

